Batu Biologics Receives FDA IND Clearance

Batu Biologics Receives FDA Clearance for First Multi-Pronged Immunotherapy Targeting the Blood Vessels that Feed Cancer

Company’s First-in-Class Drug, ValloVax, Acts by Educating Immune System to Starve Tumors

Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax™, has received an Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) allowing Batu to proceed with Phase 1 clinical trials.

Read the full article at businesswire.com

Continue →
0

Batu Chooses Unusual Path, Unusual Weapon

Crowdfunding Part of Financial Strategy; Cancer Fight Aims to Cut Tumors’ Blood Supply

When it comes to small and scrappy biotechs, Batu Biologics might take the cake. Led by a 25-year-old college dropout, Batu got its start with a $100,000 infusion of cash from a crowdfunding campaign the team launched online… the company has filed 29 patents, raised over $2 million, and is gearing up to start testing its anti-cancer vaccine in humans.

Download full article here

Continue →
0

Batu Publishes Oncotarget Paper

Batu Biologics Publishes Mechanistic Preclinical Data for ValloVax

Company authors peer reviewed publication describing the mechanism of action of the ValloVax™ mediated immune response

Batu Biologics, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today the publication of mechanistic data for the ValloVax platform in the current issue of Oncotarget.

Read the full article at businesswire.com

Continue →
0

Batu announces formation of Clinical Advisory Board

Batu Biologics Welcomes Three Visionary Leaders to Its Newly Formed Clinical Advisory Board

CAB to oversee the clinical development of Batu Biologics’ tumor vasculature targeting immunotherapeutic, ValloVax™

Batu Biologics, a San Diego based immuno-oncology company focused on the development of its tumor angiogenesis targeting immune therapy, ValloVax™, announced today the formation of a Clinical Advisory Board to guide the company in the development of its lead program.

Read the full article at businesswire.com

Continue →
0

Batu Recruits Internationally Recognized Immunologist

Internationally-Recognized Immunologist Joins Batu Biologics’ Quest to Destroy Solid Tumors

Francesco Marincola, MD, Joins Batu’s Scientific Advisory Board

Batu Biologics, an immuno-oncology company dedicated to the development of its tumor endothelium vaccine, ValloVax™, announced today the appointment of Francesco M. Marincola, MD, FACS, to its scientific advisory board.

Read the full article at businesswire.com

Continue →
0

Batu Seeks New Approach to Inhibit Immune Checkpoints

Batu Biologics Utilizes CRISPR/cas9 Gene Editing to Modify T Cells

Immune Checkpoint Silenced T Cells for More Potent, Longer Lasting Anti-Tumor Responses

Batu Biologics, an immuno-oncology company, has recently filed intellectual property and initiated discovery research on a new method of augmenting an anti-tumor immune response through ex vivo manipulation of the patient’s T cells.

Read the full article at businesswire.com

Continue →
0

ValloVax Efficacy Augmented by Checkpoint Inhibitors

Batu Biologics Reports Combination Therapy Boosts Results in Tumor Blood Vessel-Killing Strategy

Company Files Patent on Second Generation Cancer Therapy

Batu Biologics, an immuno-oncology company dedicated to the commercialization of its first-in-class tumor blood vessel targeting vaccine, ValloVax, reported today filing of a patent application covering a unique combination therapy of its vaccine together with two classes of “checkpoint inhibitors.”

Read the full article at businesswire.com

Continue →
0
Page 1 of 4 1234